Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy - PubMed (original) (raw)
Comparative Study
Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy
P Rietschel et al. J Clin Endocrinol Metab. 2001 Feb.
Abstract
Human immunodeficiency virus (HIV) lipodystrophy (LIPO) is characterized by increased visceral adiposity, peripheral fat atrophy, dyslipidemia, and insulin resistance. GH concentrations are known to vary inversely with excess weight and body fat but have not been investigated in HIV lipodystrophy. Twenty-one subjects with HIV LIPO, 20 HIV-infected nonlipodystrophy subjects (NONLIPO), and 20 control (C) subjects were prospectively recruited for this study and compared. Subjects in the three groups were all male, age-matched [median, 47 yr old (interquartile range, 37-50) LIPO; 41 (37-44) NONLIPO; and 43 (37-49) C], and body mass index-matched [median, 24.3 kg/m(2) (interquartile range, 22.2-26.6) LIPO; 24.4 (23.3-25.9) NONLIPO; and 24.8 (22.7-26.1) C] (P: > 0.05 for all comparisons). Visceral abdominal fat [16,124 mm(2) (11,246-19,790) LIPO; 7,559 (5,134-11,201) NONLIPO; and 8,803 (6,165-11,623) C; P < 0.01 LIPO vs. NONLIPO and LIPO vs. C] and the ratio of visceral abdominal fat to sc abdominal fat [1.37 (0.71-2.44) LIPO vs. 0.57 (0.47-0.78) NONLIPO vs. 0.55 (0.41-0.71) C, P < 0.01 LIPO vs. NONLIPO and LIPO vs. C] were significantly increased in the LIPO subjects but were not significantly different between NONLIPO and C. The mean overnight GH concentration, determined from frequent sampling every 20 min (from 2000 h to 0800 h) was decreased in the LIPO subjects [0.38 microg/L (0.13-0.67) LIPO vs. 0.96 (0.53-1.30) NONLIPO vs. 0.81 (0.49-1.03) C, P < 0.05 LIPO vs. NONLIPO and LIPO vs. C] and not significantly different between NONLIPO and C. Pulse analysis demonstrated decreased baseline GH [0.08 microg/L (0.06-0.21) LIPO vs. 0.19 (0.10-0.32) NONLIPO vs. 0.17 (0.12-0.57) C, P < 0.05 LIPO vs. NONLIPO and LIPO vs. C] and GH peak amplitude [1.06 microg/L (0.46-1.94) LIPO vs. 2.47 (1.22-3.43) NONLIPO and 2.27 (1.36-4.25) C, P < 0.05 LIPO vs. NONLIPO and LIPO vs. C] in the LIPO subjects but no significant difference in pulse frequency. No significant differences were observed between NONLIPO and C for any GH parameter. Insulin-like growth factor-I was not different between the groups. Total body fat (r = -0.40, P = 0.01) and visceral fat (r = -0.58, P = 0.0001) correlated inversely with mean overnight GH concentrations in the HIV-infected patients. In a multivariate regression model, controlling for age, body mass index, body fat, and visceral fat, only visceral fat was a significant predictor of mean GH concentrations (P = 0.0036, r(2) for model = 0.40). These data demonstrate normal GH pulse frequency and insulin-like growth factor-I concentrations but reduced mean GH concentrations, basal GH concentrations, and GH pulse amplitude in patients with HIV lipodystrophy. Increased visceral adiposity is the strongest predictor of reduced GH concentrations in HIV lipodystrophy. Further studies are necessary to determine the clinical significance of reduced GH in patients with HIV lipodystrophy.
Similar articles
- Hyperandrogenemia in human immunodeficiency virus-infected women with the lipodystrophy syndrome.
Hadigan C, Corcoran C, Piecuch S, Rodriguez W, Grinspoon S. Hadigan C, et al. J Clin Endocrinol Metab. 2000 Oct;85(10):3544-50. doi: 10.1210/jcem.85.10.6923. J Clin Endocrinol Metab. 2000. PMID: 11061499 Clinical Trial. - Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in human immunodeficiency virus-infected subjects with fat redistribution.
Meininger G, Hadigan C, Laposata M, Brown J, Rabe J, Louca J, Aliabadi N, Grinspoon S. Meininger G, et al. Metabolism. 2002 Feb;51(2):260-6. doi: 10.1053/meta.2002.29999. Metabolism. 2002. PMID: 11833059 - Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy.
Andersen O, Haugaard SB, Hansen BR, Orskov H, Andersen UB, Madsbad S, Iversen J, Flyvbjerg A. Andersen O, et al. Scand J Infect Dis. 2004;36(11-12):832-9. doi: 10.1080/00365540410021162. Scand J Infect Dis. 2004. PMID: 15764170 Clinical Trial. - Growth hormone deficiency and human immunodeficiency virus.
Rochira V, Guaraldi G. Rochira V, et al. Best Pract Res Clin Endocrinol Metab. 2017 Feb;31(1):91-111. doi: 10.1016/j.beem.2017.02.006. Epub 2017 Feb 24. Best Pract Res Clin Endocrinol Metab. 2017. PMID: 28477736 Review. - Recombinant human growth hormone: rationale for use in the treatment of HIV-associated lipodystrophy.
Benedini S, Terruzzi I, Lazzarin A, Luzi L. Benedini S, et al. BioDrugs. 2008;22(2):101-12. doi: 10.2165/00063030-200822020-00003. BioDrugs. 2008. PMID: 18345707 Review.
Cited by
- Dietary regimens appear to possess significant effects on the development of combined antiretroviral therapy (cART)-associated metabolic syndrome.
Chege BM, Mwangi PW, Githinji CG, Bukachi F. Chege BM, et al. PLoS One. 2024 Feb 28;19(2):e0298752. doi: 10.1371/journal.pone.0298752. eCollection 2024. PLoS One. 2024. PMID: 38416754 Free PMC article. - Effect of tesamorelin in people with HIV with and without dorsocervical fat: Post hoc analysis of phase III double-blind placebo-controlled trial.
Rahman F, McLaughlin T, Mesquita P, Morin J, Potvin D, De Chantal M, Aberg JA. Rahman F, et al. J Clin Transl Sci. 2022 Dec 7;7(1):e40. doi: 10.1017/cts.2022.515. eCollection 2023. J Clin Transl Sci. 2022. PMID: 36845310 Free PMC article. - Viruses and Endocrine Diseases.
Nekoua MP, Debuysschere C, Vergez I, Morvan C, Mbani CJ, Sane F, Alidjinou EK, Hober D. Nekoua MP, et al. Microorganisms. 2023 Jan 31;11(2):361. doi: 10.3390/microorganisms11020361. Microorganisms. 2023. PMID: 36838326 Free PMC article. Review. - Approach to the Patient With Lipodystrophy.
Fourman LT, Grinspoon SK. Fourman LT, et al. J Clin Endocrinol Metab. 2022 May 17;107(6):1714-1726. doi: 10.1210/clinem/dgac079. J Clin Endocrinol Metab. 2022. PMID: 35137140 Free PMC article. - HIV and the Pituitary Gland: Clinical and Biochemical Presentations.
Youssef J, Sadera R, Mital D, Ahmed MH. Youssef J, et al. J Lab Physicians. 2021 Mar;13(1):84-90. doi: 10.1055/s-0041-1723055. Epub 2021 May 19. J Lab Physicians. 2021. PMID: 34054243 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical